Answers are grounded in this paper and cite their sources.
The advent of next-generation imaging will likely reduce nonmetastatic prostate cancer (PC) prevalence and increase identification of metastatic prostate cancer cases, resulting in two predominant advanced stages in the metastatic setting. There is a need to characterize changes in health care resource utilization (HRU) and costs when metastatic castration-sensitive PC (mCSPC) progresses to metastatic castration-resistant PC (mCRPC) to identify value drivers from current and new treatments.
No takes yet. Share an insight, caveat, or question.
Kaye et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: